5 completed, 2 terminated, 1 active not recruiting, 1 withdrawn. 9 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 9 | Completed 5, Terminated 2, Active not recruiting 1, Withdrawn 1 |
| Phase 2 | 3 | Active not recruiting 1, Completed 1, Terminated 1 |
Follow denileukin diftitox: new trials by email Literature Review of denileukin diftitox trials Research Report on denileukin diftitox
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| T-regulatory Cell Depletion With E7777 Combined With Pembrolizumab in Recurrent or Metastatic Solid Tumors Pembrolizumab, E7777 - Epithelial Ovarian Cancer | Phase 1 / Phase 2 | Active not recruiting | Alexander B Olawaiye, MD | 25 | 2022-09-30 | 2026-05-29 |
| E7777 for the Treatment of Patients With Peripheral T-Cell Lymphoma denileukin diftitox (E7777) - Peripheral T-Cell Lymphoma | Phase 1 | Completed | Eisai Co., Ltd. | 13 | 2011-07-01 | 2018-11-23 |
| Dose Escalation Trial of Denileukin Diftitox (Ontak) Post Autologous Transplantation Denileukin Diftitox (Ontak) - Multiple Myeloma | Phase 1 | Terminated | Barbara Ann Karmanos Cancer Institute | 2 | 2010-11-01 | 2017-06-20 |
| Therapeutic Autologous Lymphocytes, Aldesleukin, and Denileukin Diftitox in Treating Patients With Stage III-IV Melanoma therapeutic autologous lymphocytes, aldesleukin, denileukin diftitox - Recurrent Melanoma, Stage III Melanoma | Phase 1 / Phase 2 | Terminated | Fred Hutchinson Cancer Center | 3 | 2009-07-01 | 2022-11-15 |
| Denileukin Diftitox Followed by Vaccine Therapy in Treating Patients With Metastatic Cancer denileukin diftitox, recombinant fowlpox-CEA(6D)/TRICOM vaccine, therapeutic autologous dendritic cells - Breast Cancer, Colorectal Cancer | Phase 1 | Completed | H. Kim Lyerly | 24 | 2005-09-01 | 2012-11-12 |
| ONTAK® in Treating Patients With Advanced Breast Cancer That Did Not Respond to Previous Treatment ONTAK, flow cytometry, immunohistochemistry staining method - Male Breast Cancer, Recurrent Breast Cancer | Phase 1 / Phase 2 | Completed | University of Washington | 15 | 2005-09-01 | 2018-12-05 |
| Lymphocytic B-Leukemia (B-CLL) w/Human IL-2 Gene Modified & Human CD40 Ligand-Expressing Autologous Tumor Cells IL-2 secreting and hCL4OL-expressing autologous B-CLL cells, IL-2, CD40L - CHRONIC LYMPHOCYTIC B-LEUKEMIA | Phase 1 | Withdrawn | Baylor College of Medicine | 2005-09-01 | 2012-05-21 | |
| Denileukin Diftitox Used in Treating Patients With Advanced Refractory Ovarian Cancer, Primary Peritoneal Carcinoma, or Epithelial Fallopian Tube Cancer denileukin diftitox, intraperitoneal administration, laboratory biomarker analysis - Fallopian Tube Cancer, Ovarian Clear Cell Cystadenocarcinoma | Phase 1 | Completed | University of Washington | 11 | 2005-04-01 | 2019-05-14 |
| Cyclophosphamide or Denileukin Diftitox Followed By Expanding a Patient's Own T Cells in the Laboratory in Treating Patients With HER-2/Neu Overexpressing Metastatic Breast Cancer, Ovarian Cancer, or Non-Small Cell Lung Cancer Previously Treated With HER-2/Neu Vaccine ex vivo-expanded HER2-specific T cells, cyclophosphamide, denileukin diftitox - HER2-positive Breast Cancer, Recurrent Breast Cancer | Phase 1 | Completed | University of Washington | 8 | 2003-06-01 | 2014-11-11 |
Breast Neoplasms (3) · Carcinoma, Ovarian Epithelial (3) · Breast Neoplasms, Male (2) · Carcinoma, Non-Small-Cell Lung (2) · Colonic Neoplasms (1) · Colorectal Neoplasms (1) · Fallopian Tube Neoplasms (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Lung Neoplasms (1) · Lymphatic Diseases (1) · Lymphoma (1) · Lymphoma, T-Cell, Peripheral (1) · Lymphoproliferative Disorders (1) · Melanoma (1) · Multiple Myeloma (1)
University of Washington (3) · Alexander B Olawaiye, MD (1) · Barbara Ann Karmanos Cancer Institute (1) · Baylor College of Medicine (1) · Eisai Co., Ltd. (1) · Fred Hutchinson Cancer Center (1) · H. Kim Lyerly (1)
United States (7) · Japan (1)
Lupe Salazar (2) · Alexander Olawaiye, MD (1) · Malcolm K Brenner, MD (1) · Mary Disis (1) · Michael A. Morse, MD (1) · Sylvia Lee (1) · Tadashi Nakanishi (1) · Zaid Al-Kadhimi, M.D. (1)
PMID 18519811, PMID 29363235, PMID 38022532, PMID 39362046
K12CA076930 (1), R21CA137647 (1)